H. Chu

Bioequivalence of the Rilpivirine/Emtricitabine/Tenofovir AlafenamideSingle-Tablet Regimen

B. Kearney, H. Cao, E. Quirk, 2016 .

Bioequivalence of Two Co-formulations of Emtricitabine/TenofovirAlafenamide Fixed-Dose Combinations with 200/10 mg and 200/25 mg

B. Kearney, J. Koziara, M. Rhee, 2016 .

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

B. Kearney, H. Cao, J. Flaherty, 2017, Pharmacology research & perspectives.

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.

R. Haubrich, H. Stellbrink, M. Das, 2019, AIDS.